Mackenzy Metcalfe

Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Federal policies that relate to possible models of pharmacare Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations National Strategy for Drugs for Rare Diseases World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry World Health Organization (WHO) issues concerning the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Income Tax Act as it relates to biopharmaceutical products Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade agreements as they relate to the biopharmaceutical industry Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

Renewal of the National Public Alerting Service, and its impact on broadcasters as last mile distributors. Lowering the administrative burden of CRTC regulatory processes on radio and television broadcasters through the elimination or rationalization of reporting requirements. Seeking short-term bridge funding for recipients of the Independent Local News Fund in view of ongoing legal delays in the distributions of funds from foreign online TV and audio streamers. S-211 - An Act respecting a national framework on sports betting advertising. Providing further context and background to MPs on this proposed legislation, including the current state of sports betting advertising. Also raising issues with federal involvement in areas of provincial jurisdiction. Spring Economic Update and Budget 2026 - Tax Deductibility of Advertising on Foreign Digital Platforms, Extension of the journalism labour tax credit to broadcast newsrooms, government advertising spending. Online Streaming Act - Implementation of the legislation to include foreign streaming services in Canada's regulated broadcasting sector. The Online News Act. Implementation of the legislation on the remuneration of broadcast news publishers for redistribution of their content through online platforms. S-269 - An Act respecting a national framework on advertising for sports betting. Providing perspective on the broadcasting sector's current approach to sports betting advertising. Bill S-210 - An Act to restrict young persons’ online access to sexually explicit material. Providing input on potential unforeseen impacts on Canadian broadcasters, including possible requirements for age-gating of legitimate digital entertainment portals. Safety Code 6 - Presentations on the regulatory updates on broadcasters transmission sites, especially for AM Radio CRTC Radio Regulations - Discussions on process of renewing the regulatory regime for radio broadcasters. Bill C-252 An Act to amend the Food and Drugs Act (prohibition of food and beverage marketing directed at children). Presenting various potential amendments to the legislation to reflect the reality of advertising in Canada.

Spring Economic Update and Budget 2026 - Tax Deductibility of Advertising on Foreign Digital Platforms, Extension of the journalism labour tax credit to broadcast newsrooms, government advertising spending. Amending the Food and Drugs Act (prohibition of food and beverage marketing directed at children); presenting various considerations to reflect the reality of advertising in Canada. The Online News Act. Implementation of the legislation on the remuneration of broadcast news publishers for redistribution of their content through online platforms. Safety Code 6 - Presentations on the regulatory updates on broadcasters transmission sites, especially for AM Radio Proposed national framework on advertising for sports betting. Providing perspective on the broadcasting sector's current approach to sports betting advertising. Online Streaming Act - Implementation of the legislation to include foreign streaming services in Canada's regulated broadcasting sector. CRTC Radio Regulations - Discussions on process of renewing the regulatory regime for radio broadcasters.

Ensure retailer flyer printing and distribution in Canada remains competitive. At a time when the news publishing industry is facing soaring costs due to inflation, advertising competition from foreign Big Tech giants, and the theft of journalistic content by AI companies, ensure Canada Post offers community newspaper publishers the same rates and level of service they are offering to the dominant commercial printer in Canada. Ensure there is healthy competition in the flyer printing and distribution markets across Canada. Amend the definition of a Qualified Canadian Journalism organization (QCJO), requiring that an organization regularly employ two or more journalists to include: journalists who do not deal at arm’s length with the organization. This would generally include owners/partners who actively pursue, research, analyze, explain, edit, format, design, write or report the news, or select, plan, or assign work, in accordance with journalistic processes and principles. They would work, on average, a minimum of 26 hours per week and spend at least 75% of their time engaged in the production of original written news content, including researching, collecting information, verifying facts, photographing, writing, editing, designing and otherwise preparing content. To halt the theft of copyright protected news content, Public Services and Procurement Canada and Treasury Board should ensure those on the government’s list of interested artificial intelligence suppliers sign a "supplier commitment to support the Government of Canada’s effort in leading the way on ethical AI” that includes a commitment to the principles of transparency, consent, and attribution with respect to all copyright-protected source content. Ensure that the Online News Act continues and that funding is distributed in accordance with the Act and its Regulations. Ensure social media services covered by the Online News Act do not allow publisher content to be reproduced (screen shots, copied text, etc.) without providing compensation to news businesses. Protect intellectual property by preventing LLMs from scraping journalistic content. Ensure search engines cannot abuse their dominant position by de-indexing Canadian news sites if publishers block their AI bots from crawling our protected content without consent, credit, and compensation. Ensure any policy changes to the Aid to Publishers component of the Canadian Periodical Fund take into account the importance of the program, especially to smaller rural community newspapers. Align the Government of Canada advertising policy with the Government of Canada's "Buy Canadian Policy" by directing the Agency of Record to ensure a minimum of 25% of the Government of Canada domestic advertising budget to Canadian private sector news businesses. Ensure Canada Post continues to perform its vital role deliver community newspapers to Canadians. Have Canada Post return to the long-standing policy of exempting community newspapers with commercial inserts (e.g., flyers from local hardware and grocery franchisees) from the Consumers’ Choice program. Community newspapers with commercial inserts are not ‘junk mail’. Ensure that the Copyright Act is not modified through an exception permitting Text and Data Mining (TDM) allowing AI companies to use Canadian news publishers' protected works to train generative AI systems without consent, credit, or compensation. For transparency and to facilitate verification of eligible news publishers under the Online News Act, make the list of Qualified Canadian Journalism Organizations public. Keep advertising in dollars in Canada by closing the loophole in Section 19 of the Income Tax Act that allows for the deductibility of foreign internet advertising. Maintaining the Canadian Journalism Labour Tax Credit at 35%. Abuse of dominance and anti?competitive business practices related to online search, search advertising and display advertising services in Canada. Extending the Local Journali

Discussions on updates to Owens Corning’s network in Canada. Discussions with officials regarding the Canada-US bilateral relationship and possible tariffs.

Build Canada Homes and surrounding legislation. RCC is an interested stakeholder as it is a pivotal player in home building supply chains and would like to be included in government planning in this area. Retail Crime and General Crime Legislation. RCC is advocating for changes to criminal justice systems to enable a decrease in violent retail crime. This includes asking for tighter bail through reform. Grocery and Cost of Food remains a high priority concern for Canadians and for the food sector. Our discussions surround cost of food and inputs, the implementation of the industry led Grocery Code of Conduct, and other relevant subjects. Government Procurement and "Buy Canada" policies. RCC discusses on a regular basis how procurement rules should not impact Canadian based companies in any negative manner. Environmental Regulations, Plastics, Recycling, Environmental Sustainability. RCC regularly engages with ECCC on the development and implementation of environmental regulations to ensure Canada's standards are competitive and enable sustainability goals of retailers CUSMA Renegotiations, trade, Canada-U.S. relations. RCC represents members who are integral members of the cross-border retail supply chains and have considerable interests in tariffs and the renegotiations of trade treaties, namely CUSMA. Tariffs being applied to retail goods is also of concern Labour disruptions that impact retail supply chains and the retail industry Safe Food for Canadian Act, formerly Bill S-11, An Act respecting food commodities, including their inspection, their safety, their labelling and advertising, their import, export and interprovincial trade, the establishment of standards for them, the registration or licensing of persons who perform certain activities related to them, the establishment of standards governing establishments where those activities are performed and the registration of establishments where those activities are performed. RCC is interested in working with government to see regulations related to food safety and consumer product safety harmonizes with similar regulations that exist in the united states. RCC is interested in seeing the elimination of import duties that still exist on finished goods. Proposed legislation and policies related to prevention of forced and child labour in Canadian supply chains. Proposed changes to the tax treatment of privately held corporations; concerns with income distribution by family businesses and passive investments. Proposed changes to the tax treatment of privately held corporations International Trade - Request for Tarriff Relief for Retail Goods Formerly Bill C-243 - An Act to Amend the Payment Card Network Act (credit card acceptance fees) Discussion of Retail Council of Canada's priorities and government intentions regarding Federal Digital Charter implementation Bill C-27 Copyright Act - with respect to possible changes introducing levies on blank media, digital rights management technology, parallel imports; changes to "notice and takedown" regulations contained within existing copyright legilsation; lobbying for exceptions for photo finishers. Consumer Product Safety Act with respect to business confidentiality provisions and recall provisions Changes to the payments industry in Canada as described in the proposed Voluntary Code of Conduct for the Debit and Credit Card Industry in Canada issued by Finance Canada. Possible legislation to regulate the payments industry in Canada, either designating the credit card companies under the Canadian Payments Act, or a similar legislative proposal. Implementation of certain provisions of "Transparency, Balance and Choice: Canada’s Credit Card and Debit Card Systems" - Report of the Senate Committee on Banking Trace and Commerce. An Act to promote the efficiency and adaptability of the Canadian economy by regulating certain activities that discourage reliance on electronic means of carrying out commercial activities, and to amend the

Government funding for the orchestra sector, notably through the Canada Council for the Arts, Department of Canadian Heritage, and FedDev Ontario.

Immigration pathways and potential carve outs for professional musicians seeking permanent residency in Canada. Government funding for the orchestra sector, notably through the Canada Council for the Arts, Department of Canadian Heritage, and FedDev Ontario.

Advocacy for tax incentives for charitable giving, as well as exploration of a live performing arts tax credit Advocating for the importance of cultural diplomacy, support for touring, partnership for trade and cultural delegations. Immediate priorities are related to the TSO's anticipated China Tour in 2028 Advocating for immigration policies and proposals that affect the ability of TSO to attract and retain highly trained foreign musicians Canada Summer Jobs program Advocating for funding for the Department of Canadian Heritage and associated budgetary matters affecting the arts and culture industry. Increasing permanent funding for the Canada Council for the Arts

Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada Annual federal Budgets and Budget updates relating to the biopharmaceutical industry. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

International trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer. Internal trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer. Funding for programs to be operated by the Canadian Cancer Society to advance cancer control. Canadian Partnership Against Cancer, as it relates to continued federal funding for the cancer control strategy Canada Health Transfer and health system bilateral funding agreements intended for provinces/territories to support the delivery of healthcare services Framework Convention on Tobacco Control, including protocols, guidelines and implementation Tobacco and Vaping Products Act, as it relates to regulations, implementation and enforcement Non-Smokers' Health Act including implementation and enforcement Food and Drugs Act and regulations, as it relates to nciotine replacement products Federal Tobacco Control Strategy, including all matters related to tobacco control Taxation, revenue measures, controlled products regulations, including implementation, for alcohol, tobacco control, products containing carcinogens and products associated with cancer. Communication regarding alcohol consumption guidance. Food and Drugs Act and regulations, as it relates to alcohol warning labels Food and Drugs Act and regulations, as it relates to restricting the advertising to children of foods high in sodium, sugars and saturated fat. Healthy Living - Supporting initiatives, legislation, regulation, policies, and programs that prevent cancer or improve the social determinants of health Adoption of HPV testing and increasing HPV vaccination rates Sustainable funding of the National Advisory Committee on Preventive Health Services to ensure timely, up?to?date cancer screening guidelines Equitable and timely access to cancer screening. Measures and funding related to the charitable sector generally Equitable access to care along the full cancer continuum for First Nations, Inuit and Métis communities Employment Insurance special benefit programs, including the sickness benefit and compassionate care benefit Canada Labour Code and Employment Insurance Act, as it relates to job-protected leave, employment insurance special benefits, return to work policies, and human rights protections for people affected by cancer Access to information and support to make decisions regarding end-of-life care, including Medical Assistance In Dying Supports for mental health during people's cancer journeys Implementation and funding of the National Grief Action Plan as part of the government's work on palliative care and mental health Canada Health Act as it relates to access to care, including long-term, home, and palliative care National Caregiving Strategy Financial supports for caregivers, including the Canada Caregiver Credit Implementation of the Framework on Palliative Care in Canada and integration of a palliative approach to care in our health system, including national standards and data, care provider training, research, and implementation of the National Grief Action Plan and distinctions?based frameworks for First Nations, Inuit and Métis people Setting and measuring pan-Canadian wait time benchmarks and targets and measures to address them, including addressing healthcare shortages, increased and sustainable funding for care, infrastructure and equipment, targeted strategic funding to PTs for workforce shortages, particularly in rural and remote communities. Sustained core funding for federal research agencies, improved coverage of indirect research costs, Canadian research sovereignty, strengthening capacity and the economic benefits of domestic research, research commercialization. Increasing access to care including models of care, removing barriers to care, particularly for underserved communities, using innovative approaches to improve access to care including AI to improve timely diagnosis and treatment. Issu

BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care. HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. HEALTH DATA INTEROPERBILITY: Provide CMA’s perspective as it relates to health data interoperability that would ensure providers have access to the right information at the right time when providing care, and improve patient outcomes and their health care experience. The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs. Improve safeguards for Canadian health data. Improve labour mobility so physicians can work across the country. Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians. MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES: Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, and advocacy on discontinuing the requirement that employees present sick notes to their employers. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada, including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian

HEALTH DATA INTEROPERBILITY: Provide CMA’s perspective as it relates to health data interoperability that would ensure providers have access to the right information at the right time when providing care, and improve patient outcomes and their health care experience. BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care. HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. HEALTH PROMOTION AND DISEASE PREVENTION: Increased investments in health and social-determinants-of-health related programs, including measures to address the opioid crisis, mental health and addictions, and the regulation of natural health products. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, the development of a Federal Disability Benefit, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, providing clarity and guidance on federal forms, and advocacy on discontinuing the requirement that employees present sick notes to their employers. The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs. Improve safeguards for Canadian health data. Improve labour mobility so physicians can work across the country. Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key s

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes. Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG). US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products. The government's Science and Technology strategy as it relates to the biopharmaceutical industry. Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations. Smart Regulations as it relates to the biopharmaceutical industry. Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits. Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization. Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services. Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting. Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products. Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive. Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health. New Substances Notification Regulations as it relates to the biopharmaceutical industry. National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Income Tax Act as it relates to biopharmaceutical products. Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharm